Clinical Trial Update: Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475 [Phase 1]

View source ↗

Summary

A Phase 1 pilot study evaluating stereotactic ablation in combination with pembrolizumab (MK-3475) for oligometastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Cancer
• Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Breast Neoplasms, Bone Neoplasms | Phase 1 | Status: COMPLETED